Literature DB >> 9267977

Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.

M J Hohol1, C R Guttmann, J Orav, G A Mackin, R Kikinis, S J Khoury, F A Jolesz, H L Weiner.   

Abstract

OBJECTIVE: To assess the correlation between cognitive dysfunction and disease burden in multiple sclerosis (MS) during a 1-year period.
DESIGN: The Brief, Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis was performed at entrance and 1 year. Patients underwent at least 20 proton density (range, 20-24) and T2-weighted axial magnetic resonance imaging (MRI) brain scans except for stable patients who were scanned monthly. Magnetic resonance imaging was evaluated using computer-automated, 3-dimensional volumetric analysis.
SETTING: A research clinic of a university hospital. PATIENTS: Forty-four patients with MS of the following disease categories: relapsing-remitting (14), relapsing-remitting progressive (12), chronic progressive (13), and stable (5). MAIN OUTCOME MEASURES: The relationships between scores on the Brief, Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis and 2 MRI measures (total lesion volume and brain to intracranial cavity volume ratio) were assessed using linear regression. These MRI measures were also compared with cognitive status at 1 year using analysis of variance.
RESULTS: Overall, there was no decline in mean cognitive test performance during 1 year. Significant correlations were found between baseline neuropsychological test scores of nonverbal memory, information-processing speed, and attention and both MRI measures. Patients with chronic progressive MS demonstrated the strongest correlations. At 1 year, change in information-processing speed and attention correlated with change in total lesion volume. The mean increase in total lesion volume was 5.7 mL for 4 patients whose cognitive status worsened compared with 0.4 mL for 19 patients who improved and 0.5 mL for 21 patients who remained stable.
CONCLUSIONS: During a 1-year period mean cognitive performance did not worsen. Automated volumetric MRI measures of total lesion volume and brain to intracranial cavity volume ratio correlated with neuropsychological performance, especially in patients with chronic progressive MS. Worsening MRI lesion burden correlated with cognitive decline.

Entities:  

Mesh:

Year:  1997        PMID: 9267977     DOI: 10.1001/archneur.1997.00550200074013

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  29 in total

Review 1.  Neuropsychiatry of the basal ganglia.

Authors:  H A Ring; J Serra-Mestres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

2.  Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation.

Authors:  Jitendra Sharma; Michael P Sanfilipo; Ralph H B Benedict; Bianca Weinstock-Guttman; Frederick E Munschauer; Rohit Bakshi
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

3.  Introducing demographic corrections for the 10/36 Spatial Recall Test.

Authors:  Adam Gerstenecker; Roy Martin; Daniel C Marson; Khurram Bashir; Kristen L Triebel
Journal:  Int J Geriatr Psychiatry       Date:  2015-08-13       Impact factor: 3.485

Review 4.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

5.  Verbal episodic memory in 426 multiple sclerosis patients: impairment in encoding, retrieval or both?

Authors:  H Brissart; E Morele; C Baumann; M Debouverie
Journal:  Neurol Sci       Date:  2012-01-13       Impact factor: 3.307

Review 6.  The neuropsychology of multiple sclerosis: contributions of neuroimaging research.

Authors:  H A Wishart; L Flashman; A J Saykin
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

7.  Cognitive impairment in probable multiple sclerosis.

Authors:  A Achiron; Y Barak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

8.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robin Conwit; Robert Naismith; Akshata Ashokkumar; Robert Bermel; Dixie Ecklund; Maxine Koepp; Jeffrey Long; Sneha Natarajan; Srividya Ramachandran; Thomai Skaramagas; Brenda Thornell; Jon Yankey; Mark Agius; Khurram Bashir; Bruce Cohen; Patricia Coyle; Silvia Delgado; Dana Dewitt; Angela Flores; Barbara Giesser; Myla Goldman; Burk Jubelt; Neil Lava; Sharon Lynch; Augusto Miravalle; Harold Moses; Daniel Ontaneda; Jai Perumal; Michael Racke; Pavle Repovic; Claire Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Gutman; Vijayshree Yadav; Aram Zabeti
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

9.  [Normalization of the Brief Repeatable Battery of Neuropsychological tests (BRB-N) for German-speaking regions. Application in relapsing-remitting and secondary progressive multiple sclerosis patients].

Authors:  P Scherer; K Baum; H Bauer; H Göhler; C Miltenburger
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

10.  Segmentation of subtraction images for the measurement of lesion change in multiple sclerosis.

Authors:  Y Duan; P G Hildenbrand; M P Sampat; D F Tate; I Csapo; B Moraal; R Bakshi; F Barkhof; D S Meier; C R G Guttmann
Journal:  AJNR Am J Neuroradiol       Date:  2008-02       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.